Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
Prashanth Rawla,1 Tagore Sunkara,2 Jeffrey Pradeep Raj3 1Department of Internal Medicine, Memorial Hospital of Martinsville and Henry County, Martinsville, VA, 2Division of Gastroenterology and Hepatology, The Brooklyn Hospital Center, Clinical Affiliate of The Mount Sinai Hospital, New York, NY, US...
Guardado en:
Autores principales: | Rawla P, Sunkara T, Raj JP |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9fc73e3d92d743d19ad5b6e9c02efeb7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease
por: Byron P. Vaughn
Publicado: (2021) -
ROLE OF TUMOR NECROSIS FACTOR ALPHA IN IMMUNE PATHOGENESIS OF DIFFERENT DISEASES AND ITS SIGNIFICANCE FOR EVOLVING ANTICYTOKINE THERAPY WITH MONOCLONAL ANTIBODIES
por: E. V. Voronina, et al.
Publicado: (2018) -
Evaluation of Therapeutic Drug Monitoring in the Clinical Management of Patients with Rheumatic Diseases: Data from a Retrospective Single-Center Cohort Study
por: Pedersen L, et al.
Publicado: (2020) -
Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
por: Javier P. Gisbert, et al.
Publicado: (2021) -
Experiencia local con natalizumab en pacientes con enfermedad de Crohn refractaria a anti-TNF: Casos clínicos
por: Fluxá,Daniela, et al.
Publicado: (2017)